Riskpilot← Back to searchSign inGet full accessVISTIN PHARMA AS
ASActiveOrg 813120232Østensjøveien 27, 0661 OsloManufacture of pharmaceutical preparations · NACE 2120Est. 201478 employees
Revenue 2024
NOK 429,5M
-2% vs 2023
EBITDA margin
25.7%
+19% vs 2023
Equity ratio
46.4%
Financial strength
Net profit 2024
NOK 66,3M
+36% vs 2023
| Revenue | NOK 429,5M | -2% |
| EBITDA | NOK 110,4M | +19% |
| Net profit | NOK 66,3M | +36% |
| Total assets | NOK 376M | -5% |
| Equity | NOK 174,3M | +64% |
| Employees | 78 | — |
Legal name
VISTIN PHARMA AS
Org number
813120232
Legal form
Aksjeselskap
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
11. februar 2014
Share capital
NOK 100 000
Employees
78 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Utvikling, produksjon og salg av legemidler, og andre helserelaterte produkter og tjenester, og det som står i forbindelse med dette, alene eller gjennom partner-/eierskap i andre virksomheter.
Address
Østensjøveien 27, 0661 Oslo
Phone
+4735984200
Email
vistin@vistin.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 253 906 | 278 623 | 304 852 | 438 328 | 429 503 |
| Staff expenses | −70 898 | −71 479 | −77 010 | −90 989 | −90 527 |
| EBITDA | 58 190 | 48 556 | 10 378 | 92 921 | 110 376 |
| Depreciation & amort. | −9 623 | −10 609 | −12 280 | −17 347 | −19 029 |
| EBIT | 48 567 | 37 947 | −1 902 | 75 574 | 91 347 |
| Net financials | −10 882 | −2 673 | −1 733 | −13 231 | −6 375 |
| Profit before tax | 37 685 | 35 274 | −3 635 | 62 343 | 84 972 |
| Tax | 8 313 | 7 620 | −771 | 13 764 | 18 699 |
| Net profit | 29 372 | 27 654 | −2 864 | 48 579 | 66 273 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 224 458 | 317 792 | 404 516 | 395 181 | 375 980 |
| Equity | 28 335 | 54 831 | 54 178 | 106 448 | 174 320 |
| Long-term debt | 98 550 | 58 024 | 58 024 | 58 024 | 0 |
| Short-term debt | 81 244 | 189 103 | 279 114 | 221 845 | 195 058 |
| Total debt | 179 794 | 247 127 | 337 138 | 279 869 | 195 058 |
EBITDA margin
25.7%
This company
15.8%
Market median
+63% vs market
20202024
Equity ratio
46.4%
This company
38.2%
Market median
+21% vs market
20202024
Return on equity
38.0%
This company
18.4%
Market median
+107% vs market
20202024
Net profit margin
15.4%
This company
8.1%
Market median
+90% vs market
20202024
Asset turnover
1.14×
This company
1.12×
Market median
+2% vs market
20202024
Debt / equity
1.16×
This company
0.62×
Market median
-87% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
SI Deputy Member | Deputy Member | 2025 |
KP Deputy Member | Deputy Member | 2025 |
AK Deputy Member | Deputy Member | 2025 |
GA Deputy Member | Deputy Member | 2025 |
| Former (7) | ||
ET Deputy Member | Deputy Member | 2021 – 2025 |
KM Deputy Member | Deputy Member | 2021 – 2023 |
FI Deputy Member | Deputy Member | 2019 – 2021 |
BS Deputy Member | Deputy Member | 2021 – 2023 |
SJ Deputy Member | Deputy Member | 2023 – 2025 |
SS Deputy Member | Deputy Member | 2023 – 2025 |
PS Deputy Member | Deputy Member | 2021 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2024 | |
| Board of Directors | 2025 | |
| Board of Directors | 2021 | |
| Former (3) | ||
| Chairman | 2021 – 2024 | |
| Board of Directors | 2021 – 2025 | |
| Board of Directors | 2019 – 2019 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Kongskilen As
VISTIN PHARMA AS Board members of VISTIN PHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Erle Tufte | Deputy Member | 0 companies |
| Kjellaug Marit Danielsen | Deputy Member | 0 companies |
| Frode Iversen | Deputy Member | 0 companies |
| Stig Isaksen | Deputy Member | 0 companies |
| Bengt Sveen | Deputy Member | 0 companies |
| Stian Johnsen | Deputy Member | 0 companies |
| Kristine Pedersen | Deputy Member | 0 companies |
| Arve Kristensen | Deputy Member | 0 companies |
| Susanne Sørdalen | Deputy Member | 0 companies |
| Petter Sørdalen | Deputy Member | 0 companies |
| Guro Amalie Øyløkken | Deputy Member | 0 companies |
| Kjell Erik Nordby | Chairman | 0 companies |
| Magnus Wilhelm Tolleshaug | Chairman | 0 companies |
| Åse Musum | Board of Directors | 0 companies |
| Stine Wang Rønningen | Board of Directors | 0 companies |
| Espen Lia Gregoriussen | Board of Directors | 0 companies |
| Gunnar Manum | Board of Directors | 0 companies |